Targeting EGFR in lung cancer: Lessons learned and future perspectives

Molecular Aspects of Medicine

Volumn 45, Issue , 2015, Pages 67-73

  Steuer, Conor E ^a   Ramalingam, Suresh S ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

EGFR; Lung cancer; NSCLC

Indexed keywords

AFATANIB; ANTINEOPLASTIC AGENT; ASTELLAS 8273; AZD 3759; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EGF 816; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; HM 61713; NIVOLUMAB; OSIMERTINIB; PACLITAXEL; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PLATINUM COMPLEX; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; ROCILETINIB; UNCLASSIFIED DRUG; ANTINEMATODAL AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; TUMOR MARKER;

CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EPITHELIAL MESENCHYMAL TRANSITION; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; HAZARD RATIO; HEALTH CARE QUALITY; HUMAN; LUNG CARCINOGENESIS; MET GENE; METASTASIS POTENTIAL; MONOTHERAPY; NON SMALL CELL LUNG CANCER; ONCOGENE; ONCOGENE EGFR; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PIK3CA GENE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SKIN TOXICITY; TREATMENT DURATION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; GENETICS; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANTINEMATODAL AGENTS; BIOMARKERS, TUMOR; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84946497475     PISSN: 00982997     EISSN: 18729452     Source Type: Journal    
DOI: 10.1016/j.mam.2015.05.004     Document Type: Review

References (59)

1. M.E. Arcila, G.R. Oxnard, K. Nafa, and et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay Clin. Cancer Res 17 2011 1169 1180
2. J. Brabender, K.D. Danenberg, R. Metzger, and et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival Clin. Cancer Res 7 2001 1850 1855
3. D.R. Camidge, Ou S.-H., G. Shapiro, and et al. Efficacy and Safety of Crizotinib in Patients with Advanced c-MET-amplified Non-Small Cell Lung Cancer (NSCLC) 2014 ASCO Chicago, USA
4. Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma Nature 511 2014 543 550
5. Y.L. Choi, M. Soda, Y. Yamashita, and et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors N. Engl. J. Med 363 2010 1734 1739
6. D.A. Cross, S.E. Ashton, S. Ghiorghiu, and et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer Cancer Discov 4 9 2014 1046 1061
7. B.J. Druker, M. Talpaz, D.J. Resta, and et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N. Engl. J. Med 344 2001 1031 1037
8. J.A. Engelman, P.A. Janne, C. Mermel, and et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines Proc. Natl. Acad. Sci. U.S.A. 102 2005 3788 3793
9. J.A. Engelman, K. Zejnullahu, T. Mitsudomi, and et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043
10. Erlotinib hydrochloride in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery (An ALCHEMIST Treatment Trial) https://clinicaltrials.gov/ct2/show/NCT02193282 (accessed 28.5.15.)
11. FLAURA AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA) https://clinicaltrials.gov/ct2/show/NCT02296125?term=flaura&rank=1 2014 (accessed 2.7.15)
12. M. Fukuoka, S. Yano, G. Giaccone, and et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J. Clin. Oncol 21 2003 2237 2246
13. M. Fukuoka, Wu Y.L., S. Thongprasert, and et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J. Clin. Oncol 29 2011 2866 2874
14. A. Hochhaus, S. Kreil, A.S. Corbin, and et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy Leukemia 16 2002 2190 2196
15. Y.Y. Janjigian, E.F. Smit, H.J. Groen, and et al. Dual inhibition of EGFR with Afatinib and cetuximab in Kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations Cancer Discov 4 2014 1036 1045
16. K. Kelly, N. Altorki, W.E. Eberhardt, and et al. A Randomized, Double-Blind Phase 3 Trial of Adjuvant Erlotinib (E) Versus Placebo (P) following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients (pts) with Stage IB-IIIA EGFR Positive (IHC/FISH) Non-small Cell Lung Cancer (NSCLC): RADIANT Results 2014 ASCO Chicago, USA
17. S. Kobayashi, T.J. Boggon, T. Dayaram, and et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N. Engl. J. Med 352 2005 786 792
18. M.G. Kris, R.B. Natale, R.S. Herbst, and et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 290 2003 2149 2158
19. M.G. Kris, B.E. Johnson, L.D. Berry, and et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs JAMA 311 2014 1998 2006
20. J.K. Lee, S. Hahn, D.W. Kim, and et al. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis JAMA 311 2014 1430 1437
21. T.J. Lynch, D.W. Bell, R. Sordella, and et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med 350 2004 2129 2139
22. M. Maemondo, A. Inoue, K. Kobayashi, and et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N. Engl. J. Med 362 2010 2380 2388
23. T. Mitsudomi, S. Morita, Y. Yatabe, and et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
24. T. Mok, Wu Y.L., K. Nakagawa, and et al. Continuation of Gefitinib Plus Pemetrexed/Cisplatin of No Clinical Benefit in NSCLC Patients with Acquired Resistance to Gefitinib 2014 ESMO Madrid, Spain
25. T.S. Mok, Wu Y.L., S. Thongprasert, and et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N. Engl. J. Med 361 2009 947 957
26. J.D. Moyer, E.G. Barbacci, K.K. Iwata, and et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase Cancer Res 57 1997 4838 4848
27. J.G. Paez, P.A. Janne, J.C. Lee, and et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
28. W. Pao, V. Miller, M. Zakowski, and et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc. Natl. Acad. Sci. U.S.A. 101 2004 13306 13311
29. W. Pao, V.A. Miller, K.A. Politi, and et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 2005 e73
30. R. Perez-Soler, A. Chachoua, L.A. Hammond, and et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J. Clin. Oncol 22 2004 3238 3247
31. Z. Piotrowska, M. Niederst, M. Mino-Kenudson, and et al. Variation in Mechanisms of Acquired Resistance (AR) among EGFR-mutant NSCLC Patients with More than One Post-Resistant Biopsy 2014 ASCO Chicago 2014
32. S.S. Ramalingam, D.R. Spigel, Chen D., and et al. Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer J. Clin. Oncol 29 2011 4574 4580
33. N. Reguart, R. Rosell, F. Cardenal, and et al. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression Lung Cancer 84 2014 161 167
34. G.J. Riely, M.G. Kris, Zhao B., and et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus Clin. Cancer Res 13 2007 5150 5155
35. N.A. Rizvi, L. Chow, H. Borghaei, and et al. Safety and Response with Nivolumab (anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (pts) with Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced NSCLC 2014 ASCO Chicago, USA
36. Rociletinib TIGER-1: safety and efficacy study of rociletinib (CO-1686) or erlotinib in patients with EGFR mutant NSCLC who have not had any previous EGFR directed therapy https://clinicaltrials.gov/ct2/show/NCT02186301?term=rociletinib&rank=3 2015 (accessed 27.02.15.)
37. R. Rosell, E. Carcereny, R. Gervais, and et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
38. V. Rusch, D. Klimstra, E. Venkatraman, P.W. Pisters, J. Langenfeld, and E. Dmitrovsky Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression Clin. Cancer Res 3 1997 515 522
39. L.V. Sequist, J. von Pawel, E.G. Garmey, and et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer J. Clin. Oncol 29 2011 3307 3315
40. L.V. Sequist, B.A. Waltman, D. Dias-Santagata, and et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors Sci. Transl. Med 3 2011 75ra26
41. L.V. Sequist, Yang J.C., N. Yamamoto, and et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations J. Clin. Oncol 31 2013 3327 3334
42. L.V. Sequist, J.-C. Soria, S. Gadgeel, and et al. First-in-human Evaluation of CO-1686, an Irreversible, Highly Selective Tyrosine Kinase Inhibitor of Mutations of EGFR (Activating and T790M) 2014 American Society of Clinical Oncology Chicago, USA
43. T. Seto, T. Kato, M. Nishio, and et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study Lancet Oncol 15 2014 1236 1244
44. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu, and et al. Erlotinib in previously treated non-small-cell lung cancer N. Engl. J. Med 353 2005 123 132
45. H. Shigematsu, Lin L., T. Takahashi, and et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J. Natl Cancer Inst 97 2005 339 346
46. D.M. Shin, J.Y. Ro, Hong W.K., and W.N. Hittelman Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis Cancer Res 54 1994 3153 3159
47. T. Shukuya, T. Takahashi, T. Naito, and et al. Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure Lung Cancer 74 2011 457 461
48. J.R. Sierra, and M.S. Tsao c-MET as a potential therapeutic target and biomarker in cancer Ther. Adv. Med. Oncol 3 2011 S21 S35
49. D.J. Slamon, B. Leyland-Jones, S. Shak, and et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med 344 2001 783 792
50. M.S. Tsao, A. Sakurada, J.C. Cutz, and et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome N. Engl. J. Med 353 2005 133 144
51. A.O. Walter, R.T. Sjin, H.J. Haringsma, and et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC Cancer Discov 3 2013 1404 1415
52. A.J. Weickhardt, B. Scheier, J.M. Burke, and et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer J. Thorac. Oncol 7 2012 1807 1814
53. Wu Y.L., Zhou C., Hu C.P., and et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Lancet Oncol 15 2014 213 222
54. Yang C.H., D.W. Kim, D. Plachard, and et al. Updated safety and efficacy from a Phase I study of AZD9291 in patients with EGFR-TKI-resistant non-small cell lung cancer (NSCLC) European Society for Medical Oncology (ESMO) Madrid, Spain 2014
55. Yang J.C., Wu Y.L., M. Schuler, and et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials Lancet Oncol 16 2015 141 151
56. H. Yoshioka, T. Mitsudomi, S. Morita, and et al. Final Overall Survival Results of WJTOG 3405, a Randomized Phase 3 Trial Comparing Gefitinib (G) with Cisplatin Plus Docetaxel (CD) as the First-Line Treatment for Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring Mutations of the Epidermal Growth Factor Receptor (EGFR) 2014 ASCO Chicago, USA
57. Yu H.A., Sima C.S., Huang J., and et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors J. Thorac. Oncol 8 2013 346 351
58. Zhou C., Wu Y.L., Chen G., and et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
59. Zhou C., Wu Y.L., Liu X., and et al. Overall Survival (OS) Results from OPTIMAL (CTONG0802), a Phase III Trial of Erlotinib (E) versus Carboplatin Plus Gemcitabine (GC) as First-Line Treatment for Chinese Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) 2012 ASCO. Chicago, USA